AzurRx BioPharma (NASDAQ:AZRX) has been given a $5.00 target price by analysts at Maxim Group in a report issued on Wednesday. The brokerage currently has a “buy” rating on the stock. Maxim Group’s price objective points to a potential upside of 152.53% from the stock’s previous close.
Several other brokerages have also recently commented on AZRX. HC Wainwright set a $8.00 target price on shares of AzurRx BioPharma and gave the company a “buy” rating in a research report on Friday, November 2nd. ValuEngine upgraded shares of AzurRx BioPharma from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Oppenheimer set a $6.00 price objective on shares of AzurRx BioPharma and gave the company a “buy” rating in a research report on Thursday, November 1st. Finally, Roth Capital initiated coverage on shares of AzurRx BioPharma in a research report on Friday, January 25th. They issued a “buy” rating and a $10.50 price objective for the company. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $7.10.
Shares of AzurRx BioPharma stock opened at $1.98 on Wednesday. AzurRx BioPharma has a 52 week low of $1.00 and a 52 week high of $3.75.
A hedge fund recently raised its stake in AzurRx BioPharma stock. Vanguard Group Inc lifted its position in AzurRx BioPharma Inc (NASDAQ:AZRX) by 2.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 413,439 shares of the company’s stock after buying an additional 8,489 shares during the period. Vanguard Group Inc owned about 2.44% of AzurRx BioPharma worth $1,063,000 as of its most recent SEC filing. Institutional investors and hedge funds own 18.89% of the company’s stock.
About AzurRx BioPharma
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
Featured Article: Quick Ratio
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.